Latest News | Biocon Biologics Settles Patent Issue; Paves Way for Launch of Biosimilar Product in Canada

New Delhi, Mar 4 (PTI) Biocon Biologics on Monday said it has inked a patent settlement agreement with Bayer Inc and Regeneron Pharmaceuticals Inc, paving the way for it to launch a biosimilar product in Canada.

The settlement pact paves the way for the introduction of Yesafili, a proposed biosimilar to Eeylea (aflibercept) injection, in the Canadian market, Biocon Biologics said in a regulatory filing.

Also Read | BPSC Recruitment 2024: Vacancies Notified For Over 46,000 Posts on bpsc.bih.nic.in, Know How to Apply.

Under the terms of the agreement, Biocon Biologics has secured a launch date for the product no later than July 1, 2025, it added.

Yesafili, an ophthalmology product, is intended for the treatment of neovascular (wet AMD), age-related macular degeneration, among other issues.

Also Read | WBPSC Food SI Admit Card 2024 Released at psc.wb.gov.in, Know Steps to Download Hall Tickets.

In March 2023, Health Canada had granted tentative approval for Yesafili (2 mg vials), subject to the resolution of any patent issues, Biocon Biologics said

The settlement resolves multiple parallel patent infringement proceedings in the Federal Court of Canada involving six patents, and associated judicial review proceedings, under Canada's Patented Medicines (Notice of Compliance) Regulations addressing pre-entry pharmaceutical patent litigation, it noted.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)